Object: To verify the efficacy and safety of the new combination of Tanacetum parthenium 150 mg, 5-hydrossitriptophan (5-HTTP) 20 mg and magne-
sium 185 mg (Aurastop ® ) in the prophylactic treatment of high frequency migraine with aura (MWA). According to the international headache classification (IHCD 3˚ beta version) the aura phenomena have a duration of 5 -60 minutes for any of the usual disturbances (visual, somatosensory and speech disturbance) but no classification describes the frequency of this phenomena. Patients who experience migraine aura emphasize the emotional impact of such a phenomenon, mostly because of the severe, though transient, disability caused by the aura symptoms (i.e., inability to work or driving a vehicle). Furthermore, a profound asthenia lasts for about 48 hours after the resolution of the painful phase. Materials and Method: 18 patients (F: n = 10, M: n = 8, mean age: 28) presenting with an ICHD-3 beta diagnosis of migraine with aura (MWA) with a frequency of more than 5 attacks of migraine with aura per month since at least 6 months, were enrolled in the survey and treated with Aurastop © twice a day for a period of 3 months. Diary cards were filled in during a 3-month period before the beginning of the survey and during the 3-month duration of the study. The reduction of MWA attacks per month was assessed as the primary end-point; the reduction of the duration and disability of the aura and of the intensity of the headache were considered as secondary end-points. Results: A statistically significant reduction of MWA attacks/month was observed: more than 95% of the patients referred a reduction >50% of the frequency, 66.6% a reduction of more than 70%, and 16.6% a complete disappearance of the attacks after the first week of therapy. More-
Introduction
Migraine ranked as the second most frequent cause of disability worldwide [1] .
Epidemiologic studies have consistently indicated that its prevalence is up to 18% in women and 6% in men in Western Countries, with a peak between 22 and 55 years [2] . Among them, about 25% suffer migraine with aura (MWA).
According to the international headache classification (IHCD 3˚ beta version) [3] the aura phenomena have a duration of 5 -60 minutes for any of the usual disturbances (visual, somatosensory and speech disturbance) but no classification describes the frequency of this phenomena.
Patients who experience migraine aura emphasize the emotional impact of such a phenomenon, mostly because of the severe, though transient, disability caused by the aura symptoms (i.e., inability to work or driving a vehicle). Furthermore, a profound asthenia lasts for about 48 hours after the resolution of the painful phase. This notwithstanding, no aura-specific therapy is available and only sparse studies tried and address this issue so far. Official guidelines from national and international societies indicate lamotrigine (50 -200 mg daily) as an effective approach to MWA in spite of the relative non-efficacy in the subtype MWoA [4] [5] [6] , but the strength of this recommendation is low (III grade).
The same is true for many nutraceutical compounds, such as, for example, Tanacetum parthenium [7] .
According to national and international guidelines, in order to reduce the global impact of migraine, first-line drugs for migraine prophylaxis include beta-blockers, calcium antagonists, anti-depressants, anti-epileptics, onabotuli-numtoxinA and phytotherapics plus magnesium [8] . It is generally accepted that a prophylactic treatment should be started in patients who present disabling migraine attacks for at least 4 days per month, and/or in the case of inefficacy of appropriate symptomatic approaches, but no mention is done for the MWA patients.
Recently, several studies have documented the efficacy of the combination of Tanacetum parthenium, 5-hydroxy tryptophan and magnesium (Aurastop © ) for Open Access Library Journal migraine treatment and prevention [9] [10] [11] [12] .
The antimigraine effect of Aurastop is supposed to be due to the potential effect of its 3 compounds. Parthenolide is an antagonist of TRPA1 and an inhibitor of CGRP release by desensitization and nociceptor defunctionalization. Such a cascade might be interrupted by parthenolide, that is, a TRPA1 receptors inhibitor and a powerful inhibitor of nitric oxide (NO) synthase and, consequently, of NO production [17] [18] [19] . Moreover, among its many actions, intracellular magnesium has a physiologic calcium-antagonist effect, resulting in a reduction of the toxic effects of calcium. On the contrary, suboptimal concentrations of this ion favor a free radical accumulation within the cell, which, in turn, may facilitate the onset of a migraine attack [20] [21] .
5-HTP influences
Based on the mechanisms described above, the combination of the three components, Tanacetum parthenium, 5-HTP, and magnesium is expected to synergistically influence the biologic pathways involved in migraine pathogenesis, and, therefore, to have a therapeutic potential in migraine prevention.
In the present study we, therefore, aimed at testing the efficacy of Aurastop ® 
Material and Methods

Results
Eighteen patients (10 females and 8 males; mean age: 28.5 ± 1.5 years) who suffered HF-MWA were enrolled. All the patients received the treatment under investigation. The results of the analysis are summarized in Table 1 and Figure 1 :
compared to the 90-day period before Aurastop was administered, we observed a significant reduction of MWA attacks/month during the treatment period. In particular, 17 patients (94.5%) reported more than 50% reduction of MWA attacks, 12 (66.6%) a reduction of more than 70%, and 3 (16.6%) a complete Figure 1 . Changes in number (a), duration (b), disability (c), and pain intensity (d), by Aurastop assumption (t 0 vs t 1 ).
disappearance of the attacks after the first week of therapy. The number of aura attacks, in particular, shifted from 438 in the 3 months (t 0 ) before Aurastop assumption to 48 during the Aurastop intake (t 1 , p < 0.001; Figure 1(a) ). The benefit conferred by Aurastop was already detectable at the end of the first month of therapy in 15 patients (83.3%) and it was maintained thereafter. A reduction of >50% of aura duration and aura-related disability was reported by 17 patients (94.5%; duration: from 42 ± 1.2 minutes during the t 0 phase to 18 ± 1.1 at the end of the t 1 phase, p < 0.001, Figure 1(b) ; aura-related disability: from a mean of 4 points in the t 0 phase to a mean of 1 point in the t 1 phase, Figure 1(c) ), and 10 patients (55.5%) reported also a reduction of the intensity of headache (VAS: from 7 ± 1.3 in the t 0 phase to 4.2 ± 0.9 at the end of the t 1 phase, p < 0.001; Figure 1(d) ). These effects were documented at the end of the first month of Aurastop assumption in 12 patients (66.6%) and was maintained thereafter.
None of the patients reported any adverse events related to treatment. 
Discussion
The results of the present study indicate that all the pre-selected clinical endpoints, including the frequency and the duration of MWA attacks, the rate of aura-related disability, as well as the intensity of pain, improved significantly in most of the patients, and, therefore, highlight the efficacy and the safety profile of the combination of Tanacetum parthenium, 5-HTP and magnesium (Aurastop) in high frequency MWA prophylaxis.
These findings lead to speculate that the combination of the 3 molecules might act synergistically on the different pathways involved in migraine pathophysiology, that is neurogenic inflammation, neural transmission, and central sensitization.
These findings are in line with those obtained by Merlo et al. [10] in a pre- 
Conclusion
In spite of the obvious methodological limitations of this observational study due to the absence of a placebo group, our findings emphasize the potential effect of Aurastop ® on the complex pathophysiological mechanisms of MWA. The combination Tanacetum parthenium + 5-HTP + magnesium appears to be a promising alternative therapy for MWA prophylaxis in patients with high frequency of attacks, with an excellent safety profile. Further clinical trials are needed to investigate its potentials in preventing migraine, either alone or in combination with other molecules.
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